Domain Invest
Thursday, 14 February 2008
The Wacky World of Generics: Risperdal Edition
›
They don't call them atypical antipsychotics for nothing. Here are two things that keep Big Pharma CEOs up at night: (1) the growing pow...
Botox, Friday Afternoon Press Calls and the Nissen Effect
›
Blaming the media will never go out of fashion, at least not when it comes to drug safety scares. Here is Schering-Plough EVP Carrie Cox, su...
Wednesday, 13 February 2008
AZ Makes Its Move in GI
›
Back in November we broke the news that AstraZeneca may be spinning out its gastrointestinal R&D. ( Those news outlets that only read th...
Nektar Takes A Deep Breath
›
Deep breath in. Deep breath out. Nektar execs, have you found your quiet place, yet? It's been a stressful few months for Nektar employe...
Sanofi Aventis: Sign of the Big Pharma Times?
›
Sanofi-Aventis’ 2007 results presentation on Tuesday provides a nice little snapshot of Big Pharma circa early 2008. The company reported ra...
Tuesday, 12 February 2008
The Blockbuster Model is Dead, Sort Of
›
The numbers are in, and it’s not a pretty picture. No, we’re not talking about today’s Potomac presidential primary . We’re referring to the...
Monday, 11 February 2008
Starring Role for Follow-On Biologics
›
You have to hand it to the players in the follow-on biologics debate: they are pulling out all the stops. Just when you thought you thought ...
›
Home
View web version
